Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Opexa Therapeutics (OPXA)

Opexa Therapeutics (OPXA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Opexa Therapeutics 2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS TX 77381 USA

www.opexatherapeutics.com P: 281-272-9331

Description:

Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes.

Key Statistics

Overview:

Market Capitalization, $K 7,430
Shares Outstanding, K 7,660
Annual Sales, $ 2,910 K
Annual Net Income, $ -7,980 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -930 K
60-Month Beta 2.05
% of Insider Shareholders 6.88%
% of Institutional Shareholders 3.50%

Growth:

1-Year Return -71.80%
3-Year Return -86.82%
5-Year Return -95.54%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -88.22%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/13/17
Earnings Per Share ttm -0.80
EPS Growth vs. Prev Qtr 25.00%
EPS Growth vs. Prev Year 70.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 09/29/15

OPXA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -157.46%
Return-on-Assets % -106.61%
Profit Margin % -274.23%
Debt/Equity 0.00
Price/Sales 2.82
Price/Cash Flow N/A
Price/Book 4.61
Book Value/Share 0.29
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar